Equally important is the recognition that not all abandoned peptide systems merit resurrection
Strengths and limitations The authors describe this as the first study to examine obesity treatment uptake in detail, combined with the direction of weight change during and after discontinuation
Follow the guidelines in this post, label every reconstituted vial, and contact your provider before guessing on whether a peptide is still good
No regulatory body Health Canada, the FDA, the EMA, the TGA, or any equivalent has approved either component compound, or the blend formulation, as a drug for human or veterinary use
All GLP-1 RAs include an FDA boxed warning for increased risk of development of medullary thyroid carcinoma (MTC) based on early murine studies